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Abstract
There are few animal models of dengue infection, especially in immunocompetent mice. Here, we describe alterations
found in adult immunocompetent mice inoculated with an adapted Dengue virus (DENV-3) strain. Infection of mice with the
adapted DENV-3 caused inoculum-dependent lethality that was preceded by several hematological and biochemical
changes and increased virus dissemination, features consistent with severe disease manifestation in humans. IFN-c
expression increased after DENV-3 infection of WT mice and this was preceded by increase in expression of IL-12 and IL-18.
In DENV-3-inoculated IFN-c
2/2 mice, there was enhanced lethality, which was preceded by severe disease manifestation
and virus replication. Lack of IFN-c production was associated with diminished NO-synthase 2 (NOS2) expression and higher
susceptibility of NOS2
2/2 mice to DENV-3 infection. Therefore, mechanisms of protection to DENV-3 infection rely on IFN-c-
NOS2-NO-dependent control of viral replication and of disease severity, a pathway showed to be relevant for resistance to
DENV infection in other experimental and clinical settings. Thus, the model of DENV-3 infection in immunocompetent mice
described here represents a significant advance in animal models of severe dengue disease and may provide an important
tool to the elucidation of immunopathogenesis of disease and of protective mechanisms associated with infection.
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Introduction
Dengue viruses (DENV) are the most prevalent mosquito-borne
RNA viruses worldwide, classified serologically into four antigen-
ically distinct types (DENV-1–4). They are transmitted to humans
by the mosquitoes Aedes aegypti and Aedes albopictus [1–3]. According
to the World Health Organization (WHO) a total of 500,000 cases
of dengue hemorrhagic fever (DHF) occur annually, and 20,000
deaths are estimated to happen every year [4–5]. The hallmark of
severe dengue infection is a transient increase in vascular
permeability, characterized by hemorrhagic manifestations,
thrombocytopenia, and hemoconcentration, resulting in plasma
leakage, which is believed to be immune mediated [4,6–7].
Furthermore, deranged liver function is very common in patients
with dengue infection and is generally manifested by the elevation
of transaminase levels representing reactive hepatitis [8–10].
Treatment of dengue fever (DF) and of the severe forms of
dengue infection is largely supportive [7,11].
The pathogenesis of DENV infection remains poorly under-
stood and involves a complex interplay of viral and host factors
[1,3,6,12–15]. The lack of a suitable animal model that emulate
dengue disease, specially the severe forms (DHF/DSS), has
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pathogenesis, immunity, drug development and vaccine design
and testing [7,16]. Several studies in mice and humans have noted
higher levels of viremia in severe dengue disease, which supports
the assertion that increased viral replication is associated with
more severe disease manifestation [17–21]. However, we and
other groups have also demonstrated that inflammatory response,
characterized by cytokine storm, also plays a fundamental role in
dengue pathogenesis [7,22–29]. Most of these studies were first
characterized in a model of dengue infection using a mouse-
adapted DENV-2 strain that mimics several clinical parameters
seen in human disease, without affecting the CNS [22,24–28]. In
addition to characterizing mechanisms associated with pathogen-
esis, the DENV-2 model showed to be adequate to study pathways
important for host resistance to infection. In this regard, we have
recently demonstrated that IFN-c production depends on IL-12
and IL-18 combined action and mediated host resistance to
DENV-2 infection in a nitric oxide-dependent manner [30].
The development of animal models of all 4 DENV serotypes is
extremely necessary and may help to determine: (i) whether
different pathogenetic mechanisms operate in the different
serotypes, (ii) the consequence of sequential infection and (iii) the
efficacy of drugs and vaccine candidates [11,31]. In this regard, in
the present study we characterize a novel model of DENV-3
infection in immunocompetent adult mice, using the same strategy
previously used for DENV-2 model. After inoculation of the
adapted DENV-3 strain, we observed the occurrence of the major
clinical manifestations of severe dengue infection, characterized by
inoculum-dependent lethality that was preceded by significant
clinical and biochemical alterations such as thrombocytopenia,
hemoconcentration, plasma extravasation, liver damage with
elevated AST/ALT levels in serum and massive cytokine
production. Moreover, DENV-3 was detected in spleen and liver
and viremia was detected from the fifth day of infection. There
was also enhanced expression of NS3 in liver and NS1
concentration in plasma. The development of animal models for
the four DENV serotypes will also allow to determine whether
mechanisms of protection to infection are similar or not among the
different serotypes. Hence, using this novel DENV-3 model, we
demonstrate that the IFN-c-induced Nitric Oxide production,
found to be essential for host resistance to DENV-2 infection [30]
plays a major role in host protection to DENV-3 infection. Mice
deficient for IFN-c and for NOS2 are markedly susceptible to
DENV-3 infection, with elevated lethality rates, more severe
disease and increased viral load after infection. Therefore, we
describe a novel model of DENV-3 infection in immunocompetent
mice that emulates many of the manifestations seen in human
disease. The present model may provide an important tool to
study host–virus interactions and mechanisms mediating protec-
tion or those associated with severe disease manifestation.
Methods
Ethics statement
This study was carried out in strict accordance with the
Brazilian Government’s ethical and animal experiments regula-
tions. The experimental protocol was approved by the Committee
on the Ethics of Animal Experiments of the Universidade Federal
de Minas Gerais (CETEA/UFMG, Permit Protocol Number 113/
09). All surgery was performed under ketamine/xylazine anesthe-
sia and all efforts were made to minimize animal suffering.
Animals
Mice deficient for IFN-c and NOS-2 were obtained from The
Jackson Laboratory and were bred and maintained at the
Gnotobiology and Immunology Laboratory of Instituto de
Cie ˆncias Biolo ´gicas. Mice deficient for IL-12p40 were kindly
provided by Dr. J. Magran through Dr. L. V. Rizzo (Instituto de
Cie ˆncias Biome ´dicas (ICB), University of Sa ˜o Paulo, Sa ˜o Paulo,
Brazil) and were bred and maintained at the Gnotobiology and
Immunology Laboratory of Instituto de Cie ˆncias Biolo ´gicas. Mice
deficient for IL-18 [32] and IFNGR1 were kindly provided by Dr.
F.Q. Cunha and were bred and maintained at the Gnotobiology
and Immunology Laboratory of Instituto de Cie ˆncias Biolo ´gicas.
All mice were on C57BL/6J genetic background (back-crossed at
least 10 times) and wild-type control C57BL/6J (WT) mice were
used. For experiments, 7–10 weeks old mice were kept under
specific pathogen–free conditions, in filtered-cages with autoclaved
food and water available ad libitum. Adult BALB/c mice (7–10
weeks) were also used. During DENV-3 virus adaptation process,
newborn and BALB/c mice of different ages (1-4 weeks old) were
maintained at the same conditions described above.
Virus
A clinical isolate of Dengue virus type 3 (DENV-3), genotype I,
was used (access number JN697379). All work with the infectious
virus was performed in a BSL-2 facility of the Laborato ´rio de
Interac ¸a ˜o Microrganismo-Hospedeiro - ICB – UFMG. Dengue
virus 3 (DENV-3) was adapted similarly as previously described
[22]. Briefly, the virus had undergone two passages intracerebrally
(ICR) in suckling mice. The brains of the moribund mice were
harvested for preparing 10% (w/v) mice brain suspension in
modified Eagle’s medium (MEM). The death of the suckling mice
was observed on day 5 after cerebral infection. After that, 10
sequential passages through BALB/c mice of different ages (1–4
weeks old) by intraperitoneal (i.p.) injection were performed. Two
sequential passages were carried out for each age group of BALB/
c mice. After each passage, the brains of the moribund mice were
harvested for preparing 10% brain suspension and then used for
the next passage. The last passage of DENV-3 obtained from the
Author Summary
Dengue is a mosquito-borne disease caused by one of four
serotypes of Dengue virus (DENV-1-4). Dengue has esca-
lated in geographic distribution and disease severity to
become the most common arboviral infection of humans.
There are no vaccines or specific therapies for dengue and
the treatment is supportive. Immunopathogenesis of
dengue disease is also poorly understood, in part, due to
of the absence of proper animal models of infection. Here,
we describe the phenotype of infection of immunocom-
petent mice with an adapted DENV-3 strain. Infection
caused an inoculum-dependent lethality that was preced-
ed by significant clinical, virological and biochemical
changes resembling the severe manifestations of human
infection. In addition, we demonstrate that IFN-c produc-
tion is essential for the host to deal with DENV-3 infection
in a manner similar to that demonstrated previously for
DENV-2. Hence, reduced IFN-c production during DENV-3
infection was associated with diminished NOS2 expression
and Nitric oxide production. Mice deficient for each of
these molecules presented more severe disease manifes-
tation and increased viral replication. Therefore, we
describe a model of DENV-3 infection in immunocompe-
tent mice that proves to be an interesting tool to study
host–virus interactions and mechanisms mediating pro-
tection or those associated with severe disease manifes-
tation.
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passages in the brain of suckling mice ICR and was collected to
produce stocks. Ten percent brain suspension served as virus stock
and was stored at 270uC. In addition, virus stocks were produced
from infected mosquito C6/36 cells, in vitro. To calculate virus
titer, plaque assays were conducted in LLC-MK2 cells as
described below. Viral titer of stock was 5,8610
6 PFU/mL of
cell supernatant. Suspension from brain of non-infected mice was
prepared in a similar way and was used as control in all
experiments. In some experiments, the suspension of the adapted
DENV-3 virus was UV-irradiated (exposure of virus stock for
15 min to a UV lamp producing irradiation predominantly at
365 nm) or heat inactivated (56uC for 1 h) before inoculation of
mice.
Experimental procedure
For infection experiments, the virus-containing brain suspen-
sions were diluted in endotoxin-free PBS (3.2 mM Na2HPO4,
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl) and injected i.p.
into mice. For the evaluation of lethality, mice were inoculated i.p.
and lethality rates evaluated every 12 h for 14 days. The various
other parameters were evaluated at 3, 5 and 7 days or daily after
i.p. inoculation of the virus. In all experiments using genetically
deficient mice, relevant WT controls were performed in parallel.
Non-infected animals were inoculated with brain suspension from
non-infected suckling-mice diluted in a similar manner. In the
experiments involving genetically deficient mice, the NI group
represents the pooled results obtained from the analysis of deficient
mice and WT non-infected mice. Results were pooled for ease
presentation.
In some experiments IL-18 was neutralized by daily i.p.
injection of 1mg/kg of recombinant human IL-18BP per animal
(hIL-18 bp), starting 1 hour after DENV-3 inoculation and lasting
until day 6 after virus inoculation. The dose was chosen based in a
previous study of [33]. Control animals received the vehicle saline
alone. The hIL-18 bp isoform was a kind gift of Dr. Amanda
Proudfoot from Merck-Serono Pharmaceuticals (Geneve, Switzer-
land). In other experiments, mice were pretreated i.p with 100 mL
anti-DENV-3 polyclonal antiserum or control serum, 60 min
before inoculation of the adapted DENV-3. The anti-DENV
serum utilized was kindly given by Dr. Ricardo Galler from
Departamento de Bioquı ´mica e Biologia Molecular do Instituto
Oswaldo Cruz-Fiocruz, RJ, Brazil [34]. Serum was obtained from
Rhesus monkeys (macaca mullata) inoculated subcutaneously on the
anterior surface of the left forearm with 0,5 ml of the viral
suspension containing 10
5 PFU of the DENV-3 H87 (13 dpi) [34].
Cell culture and in vitro infection studies
Murine bone marrow cells were isolated from femurs and were
differentiated into myeloid DCs after culturing (change on days 3,
6, and 8) at 2610
6 cells/ml for 10 days in RPMI supplemented
with 10% FCS and 4% J558L cell-conditioned medium as a
source of GM-CSF as described [35]. DCs were plated in 96-well
microculture plates (at 2610
5 cells/well in DMEM supplemented
with 2 mM L-glutamine and 2610
25 M 2-ME) and for infection,
cells were incubated with 50 mL of the brain suspension containing
DENV-3 at a MOI of 0,05 PFU/cell in the presence or not of
IFN-c (100 U/ml). Negative controls were stimulated with sterile
brain suspensions submitted to the same procedures of the DENV-
3 containing brain homogenate. For positive controls, cells were
stimulated with TLR4 agonist LPS (Escherichia coli, serotype
O111:B4, Sigma-Aldrich, at 100 ng/ml). Cell supernatants were
harvested after 72 h of stimulation for nitrite measurements by
Griess reagents.
Quantification of nitrite in cell supernatants
Cell-free culture medium was obtained by centrifugation and
assayed for nitrite content, determined by the Griess method [36].
For this assay, 0.1 ml of culture medium or serum was mixed with
0.1 ml of Griess reagent in a multiwell plate, and the absorbance
at 550 nm read 10 min later. The NO2
2 concentration was
determined by reference to a NaNO2 standard curve (1 to
200 mM).
Estimation of nitric oxide production ex vivo
Diaminofluorescein diacetate (DAF-2DA), a non-fluorescent cell
permeable dye, was used. For NO estimation, esplenocytes of non-
infected and DENV-3- infected mice were isolated (10
6 cells/well)
and incubated with 10 mM, DAF-2DA for 30 min at 37uC and
fluorescence was determined in a fluorometer (Synergy 2,
BIOTEK, USA) at excitation wave length 488 nm and measuring
emission at 515 nm. Data were expressed as mean 6 SEM of fold
increase of fluorescence over stained-esplenocytes of NI mice.
Titration of virus
Mice were assayed for viral titers in blood, brain, spleen and
liver. Blood samples (50 mL) were collected in heparinized tubes,
diluted in 450 mL of endotoxin-free PBS (3.2 mM Na2HPO4,
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl) and stored at
270uC. For virus recovery in brain, spleen and liver, the organs
were collected aseptically in different time points and stored at
270uC until assayed for DENV-3 virus. Tissue samples were
weighed, grounded by using a pestle and mortar and prepared as
10% (w/v) homogenates in minimal essential medium (MEM)
without fetal bovine serum (FBS). Viral load in supernatants of
tissue homogenates and blood samples were assessed by direct
plaque assay using LLC-MK2 cells as described [24,27]. In Brief,
LLC-MK2 cells were seed in 6 well plates and grown to
confluence. 24 hours later, cell layers were incubated with serially
diluted 0.4 mL of virus samples for 1 and half hour and overlaid
with 1,5% methylcellulose +199 medium, 3% FBS. Plates were
incubated for 7 days at 37uC, fixed in 10% formaldehyde, and
stained with 1% crystal violet in water for 30 min. Plaques were
counted by eye. The results were measured as plaque forming
units (PFU) per gram of tissue weight or per mL of blood. The
limit of detection of the assay was 100 PFU/g of tissue, or per mL.
In vitro plaque purification
Plaque purification was performed as previously described [37].
Briefly, LLC-MK2 cells were seeded in a 6-wells plate and grown
to 80% confluence. Then, cells were infected with different
inoculums of the brain adapted DENV-3, overlaid with agarose
0,5% prepared in DMEM 5% FBS. Culture was incubated at
37uC, 5% CO2 for 7 days and single plaques were picked for
expansion in LLC-MK2 cells. Nine clones were obtained and were
titrated in LLC-MK2 cells for further in vivo evaluation.
Evaluation of blood parameters
Blood was obtained from the cava vein in heparin-containing
syringes at the indicated times under ketamin and xylazine
anesthesia (150 mg/Kg and 10 mg/Kg, respectively) .The final
concentration of heparin was 50 u/ml. Platelets were counted in a
Neubauer chamber. Briefly, 10 ul of solution (amonium oxalate
1% and blood in a dilution of 1:100) were placed in the chamber
and platelets were visualized in a Nikon XP-1000 microscope,
magnification of 4006, using phase contrast. Results are presented
as number of platelets per ml of blood. For the determination of the
hematocrit, a sample of blood was collected into heparinized
DENV-3 Infection and IFN-g-Mediated Protection
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Hematocrit centrifuge (Fanem, Sa ˜o Paulo, Brazil).
Detection of Dengue Virus NS1 Antigen
Dengue virus NS1 antigen was measured in individual serum
samples (1:3 dillution), using a commercially ELISA available kit
(BIO-RAD Platelia
TM Dengue NS1 AG). The optical density
reading obtained with a spectrophotometer set at 450 nm was
proportional to the amount of NS1 antigen present in the sample.
Results are expressed as absorbance at 450 nm.
Measurement of cytokines/chemokine concentrations
The concentration of cytokines (TNF-a, IFN-c, IL-6, IL-12p40
and IL-18) in serum or tissue samples was measured using
commercially available antibodies and according to the procedures
supplied by the manufacturer (R&D Systems, Minneapolis, except
for IL-18, manufactured by BD Pharmingen). Results are
expressed as pg/mL or pg/100 mg of tissue. The detection limit
of the ELISA assays was in the range of 4–8 pg/ml.
Evaluation of changes in vascular permeability
The extravasation of Evans blue dye into the tissue was used as
an index of increased vascular permeability, as previously
described [38]. Briefly, Evans blue (20 mg kg
21) was administered
i.v. (1 ml kg
21) via an eye vein 30 min prior to mice sacrifice.
After that, one lobe of liver and the left lung were cut and allowed
to dry in a Petri dish for 24 h at 37.
C. The right ventricle was
flushed with 10 ml of phosphate-buffered saline (PBS) to wash the
intravascular Evans blue in the lungs. The left lung was then
excised and used for Evans blue extraction. The dry weight of the
tissue was calculated and Evans blue extracted using 1 ml of
formamide (24 h at room temperature). The amount of Evans blue
in the tissue was obtained by comparing the extracted absorbance
with that of a standard Evans blue curve read at 620 nm in an
ELISA plate reader. Results are presented as the amount of Evans
blue per mg per 100 mg of tissue.
Transaminase activity
The transaminases Aspartate aminotransferase (AST) and
Alanine aminotransferase (ALT) activity were measured in
individual serum samples, using a commercially colorimetric
available kit (Bioclin, Quibasa, Belo Horizonte, Brazil). Results are
expressed as the mean mean 6 SEM of transaminase concentra-
tion in U/dL of plasma.
Body weight and hemodynamic measurements
Body weight (BW) and systolic blood pressure (SBP) were
measured in uninfected and infected mice on days 0,3,4,5,6 and 7
after infection. All animals were habituated to the blood pressure
measurement device for 7 days. SBP was determined with tail-cuff
plethysmography method in unanesthetized mice, as previously
described [39]. All data are expressed as mean 6 SEM. Changes
in SBP from baseline are expressed as absolute values as well as
areas under the BP curves.
Hypernociception assessment by a modified electronic
pressure-meter test for mice
Hypernociception was assessed as described by Sachs et al, 2010
[40]. Briefly, mice were placed in acrylic cages with a wire grid
floor 15–30 min before testing for environmental adaptation. In
these experiments, an electronic pressure-meter was used. It
consists of a hand-held force transducer fitted with a polypropyl-
ene tip (INSIGTH Instruments, Ribeira ˜o Preto, SP, Brazil) [41]. A
standard large tip (0.5 mm
2) was applied in the hind paw of the
DENV-3 infected mice or it respective controls and an increasing
perpendicular force was applied to the central area of the plantar
surface of the hind paw to induce the flexion of the knee joint,
followed by paw withdraw. After the flexion-elicited withdrawal
threshold, the intensity of the pressure was automatically recorded.
The value for the response was obtained by averaging three
measurements. Animals were tested daily after inoculation. Results
are expressed as D withdrawal threshold (g) calculated by
subtracting zero-time mean measurements from the time interval
mean measurements.
Conventional PCR and real time PCR
For typing of adapted-DENV-3 virus, RNA was extracted with
QIAMP viral RNA kit (Qiagen, Hilden, Germany) from the
adapted-DENV-3 after different passages in C6/36 mosquito cells
and of clone 4 obtained from the adapted DENV-3. The non-
adapted DENV-3 was also used as control. First-strand cDNA
synthesis for subsequent PCR assays was performed with
approximately 400 ng of total RNA and random primer C118A
(PROMEGA, Madison). A PCR assays was performed with
specific primer combinations D1/TS3 (DENV-3), previously
described by [42]. PCR products were run on a 1.5% agarose
gel stained with ethidium bromide.
For evaluation of NOS2 mRNA expression, spleens were
removed 3, 5 and 7 days after DENV-3 inoculation into mice.
Total RNA was isolated from tissues by using a QIAGen RNEasy
RNA Isolation Kit. The RNA obtained was resuspended in diethyl
pyrocarbonate treated water and stocked at 270uC until use.
Real-time RT-PCR was performed on a StepOne sequence-
detection system (Applied Biosystems) by using SYBR Green PCR
Master Mix (Applied Biosystems) after a reverse transcription
reaction of 2 mg of RNA by using M-MLV reverse transcriptase
(Promega). The relative level of gene expression was determined
by the comparative threshold cycle method as described by the
manufacturer, whereby data for each sample were normalized by
18S ribosomal RNA and expressed as a fold change compared
with non-infected controls or medium cultivated cells. The
following primer pairs were used: 18S ribosomal RNA,5 9-
CGTTCCACCAACTAAGAACG-39 (forward) and 59-CTCAA-
CACGGGAAACCTC AC-39 (reverse); and nos2,5 9- AG-
CACTTTGGGTGACCACCAGGA-39 (forward) and 59- AGC-
TAAGTATTAGAGCGGCGGCA -39 (reverse).
FACS analysis
Spleen cells were evaluated ex vivo for extracellular molecular
expression patterns and for intracellular cytokine expression
patterns. Briefly, spleens were removed from infected mice on
day 7 after infection and cells were isolated, and immediately
stained for surface markers, fixed with 2% formaldehyde and then
permeabilized with a solution of saponin and stained for 30 min at
room temperature, using anti-IFN-c monoclonal antibodies
directly conjugated with FITC. Preparations were then analyzed
using a FACScan (Becton Dickinson), gating on a total lympho-
cyte/monocyte population. The antibodies used for the staining
were rat immunoglobulin control(s), anti-CD4-PE, anti-CD8-PE,
anti-NK1.1-PE, anti-CD3-biotin and anti-IFN-c-FITC (all from
Biolegend Inc). For detection of CD3 staining, cells were
incubated with streptavidin conjugated to PE-Cy5 fluorochrome
(Serotec Inc) for 30 min at 4uC before fixing. Spleen cells were
analyzed for their intracellular cytokine expression patterns and
frequencies using the software Flow Jo 7.2 (Tree Star Inc). The
frequency of positive cells was analyzed using a gate that included
lymphocytes, large blast lymphocytes and monocytes/macrophag-
DENV-3 Infection and IFN-g-Mediated Protection
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negative populations and isotype controls.
Histopathological analysis
Liver samples from adult euthanized mice were obtained at the
indicated time points. Afterwards, they were immediately fixed in
10% buffered formalin for 24 hours and embedded in paraffin.
Tissue sections (4 mm thicknesses) were stained with hematoxylin
and eosin (H&E) and evaluated under a microscope Axioskop 40
(Carl Zeiss, Go ¨ttingen, Germany) adapted to a digital camera
(PowerShot A620, Canon, Tokyo, Japan). Histopathology score
was performed according to a set of custom designed criteria
modified from [43] evaluating hepatocyte swelling, degeneration,
necrosis and hemorrhage, added to a five-points score (0, absent;
1, minimal; 2, slight; 3, moderate; 4, marked; and 5, severe) in
each analysis. For easy interpretation, the overall score was taken
into account and all the parameters totalized 20 points. A total of
two sections for each animal were examined and results were
plotted as the media of damage values in each mouse.
Immunohistochemistry analysis
For immunohistochemistry, sections were treated with 3%
H2O2 diluted in Tris-buffered saline (TBS) (pH 7.4) for 30 min-
utes. For antigen retrieval, tissue sections were immersed in citrate
buffer (pH 6.0) for 20 minutes at 95uC. For NOS2 detection the
slides were then incubated with the rabbit polyclonal anti-NOS2
(N-20, sc-651, Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:100; at 4uC overnight in a humidified chamber. For detection
and quantification of DENV-3 infected cells an anti-DENV NS3
MAb E1D8 or an isotype control was used in a dilution of 1:350
for liver and 1:100 for brain; at 4uC overnight in a humidified
chamber. After incubation, tissue sections were washed with TBS
and treated with a labeled streptavidin-biotin kit EnVisionH +
Dual Link System-HRP (Dako). Sections were then rinsed in PBS
with 3,39-diaminobenzidine tetrahydrochloride (K3468, Dako) for
5 minutes and stained with Mayer’s hematoxylin. For quantifica-
tion of NOS-2
+ cells or NS3
+ cells, cells counts were performed in
10 alternate microscopic high-power fields (6400) for each sample
(4–5 mice per group). It was counted the number of positive
hepatocytes, kupffer cells and inflammatory cells in each field.
Areas of necrosis and hemorrhage were excluded from the
analysis. The distribution of NS3 was assessed throughout the
brain on at least two different brain coronal sections.
Intravital confocal microscopy
Liver intravital microscopy was performed as previously
described [44]. Briefly, mice were anesthetized as describe
previously. Mice were placed in a right lateral position on an
adjustable microscope stage. A lateral abdominal incision along
the costal margin to the midaxillary line was made to exteriorize
the liver, and all exposed tissues were moistened with saline-soaked
gauze to prevent dehydration. The liver was placed on a stage for
an upright microscope and the liver surface was then covered with
a coverslip to hold the organ in position. The liver was visualized
using intravital multiphoton and confocal microscopy system
based on a modified Olympus confocal microscope (FV300) in an
up- right configuration (BX51 Microscope). The images presented
were obtained using the confocal laser at 488 nm using a 10/0.30
UplanFLN objective. Cells were fluorescently labeled by rhoda-
mine 6G (0,05%; i.v.) to assess hepatocyte size by measuring the
longest cell axis of 20–30 cells/field (Image J, NIH, USA).
Sinusoids were labeled by i.v. injection of phycoerythrin-anti
PECAM-1 (0,5 mg/mice ; PE anti-CD31, clone 390 ; Ebioscience,
USA) and the percentage of perfused sinusoids was assessed by
digital quantification of the area fraction stained by the antibody
(Image J, NIH, USA).
Statistical analysis
Results are shown as means 6 S.E.M. Percent inhibition was
calculated by subtracting the background values obtained in non-
infected animals. Differences were compared by using analysis of
variance (ANOVA) followed by Student-Newman-Keuls post-hoc
analysis. Differences between lethality curves were calculated using
Log rank test (Graph Prism Software 4.0). Changes in SBP from
baseline are expressed as absolute values as well as areas under the
BP curves. Results with a P,0.05 were considered significant.
Results
Disease parameters in immunocompetent mice infected
with an adapted strain of DENV-3
Infection of adult C57BL/6j (Figure 1A) or BALB/c (Figure
S1A) mice with an adapted strain of DENV-3 induced an
inoculum-dependent lethality that was usually observed around
the 7
th or 6
th days after inoculation of DENV-3, respectively. Next,
we performed series of experiments to characterize the disease
caused by the adapted DENV-3 in both mice strains. In all
experiments, control mice were inoculated with brain suspension
which caused no clinical or biochemical alterations in comparison
with non-inoculated mice (data not shown). Infection kinetic
studies were carried out with an inoculum of 10LD50 and 1LD50
for C57BL/6j and BALB/c mice strains, respectively. Inoculi were
equivalent to 1000 and 100 PFU, respectively, as verified by
plaque assay in LLC-MK2 cells. Experiments were conducted till
day 7, the peak of infection, as there was significant lethality in
WT mice after this period (Figures 1A and S1A). Lethality of both
strains of adult mice infected with DENV-3 was preceded by
significant changes in clinical and biochemical parameters as
shown in Figures 1, 2 and S1. There was marked weight loss,
beginning at day 4 after infection, reaching about 20% on day 7
after DENV-3 inoculation (Figure 1B and S1B). There was also
significant hypernociception in response to mechanical stimula-
tion, an index of pain in experimental animals, lasting from day 3
until day 7 post-infection (Figure 1C and S1C). In addition,
DENV-3 infection induced significant hematological alterations.
Thrombocytopenia was observed as early as 3 days after infection
and platelets counts were around 50% of normal at day 7
(Figure 1D and S1D, right panels). The hematocrit, a marker of
hemoconcentration, was elevated from day 3 and increased to
greater than 50% by day 7 (Fig. 1D and S1D, left panel). In
addition to hemoconcentration, there was marked plasma
extravasation in target organs, as assessed by increase in
concentration of Evans blue dye in liver and lungs, respectively
(Fig. 1E). These findings were accompanied by changes in
hemodynamic parameters, showed by reduction in systolic blood
pressure, more sharply on day 7 p.i. Hence, at this time point,
there was a striking 40 mmHg fall in systolic blood pressure in
DENV-3-infected mice (Figure 1F). The concentration of liver
enzymes in serum (Aspartate aminotransferase [AST] and Alanine
aminotranferease [ALT]) were elevated after DENV-3 infection.
There was an increase of AST and ALT of approximately 10 and
30 times, respectively, at day 7 after infection in both strains
(Figure 1G and S1E). Evaluation of the liver microvasculature by
intravital confocal microscopy revealed a significant increase in
hepatocyte diameter at day 7 after DENV-3 inoculation as
compared to non-infected mice (Figure S2A). There was a
decrease of sinusoidal perfusion which paralleled the increase in
hepatocyte diameter (Figure S2B). The levels of IL-6, TNF-a,
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of infected mice. Overall, there was a good correlation between
levels of cytokines in serum and spleen and the severity of disease
(Figure 1H-L). IL-6 levels were elevated at 5 and 7 dpi in spleen
and 7 dpi in serum after DENV-3 inoculation (Figure 1H). Levels
of TNF-a rose rapidly from day 3 in spleen and serum of infected
mice, peaking on day 7 (Figure 1I). Nevertheless, IFN-c peaked on
day 5, and still remained elevated at day 7 in spleen and serum of
DENV-3 infected mice as compared to NI group (Figure 1J).
There were detectable levels of both IL-12/23p40 (Figure 1L, left
panel) and IL-18 (Figure 1L, right panel) cytokines in the spleen of
WT mice already on day 5 of infection. IL-18 levels reduced to
basal values at the 7
th day of infection, while IL-12/23p40
remained above background levels at this time point (Figure 1L
right and left panels, respectively).
Of note, neither limb paralysis nor any other sign of CNS
inflammation (eg. levels of TNF-a and IL-6 in brain) were noticed
after peripheral inoculation of DENV-3 into adult mice (data not
shown). Therefore, in summary, we show that immunocompetent
adult mice infected systemically with an adapted strain of DENV-3
virus presented several clinical and pathological systemic features
that resemble severe dengue disease in humans.
Characterization of virological and histopathological
parameters in immunocompetent mice infected with
DENV-3
After inoculation, the virus was detected from day 3 in the
spleen (Figure 2A and S3A), from day 5 in liver (Figure 2B and
S3B), and there was significant viremia from day 5 p.i. (Figure 2C
and S3C) in C57BL/6j and BALB/c mice, respectively. Viral load
escalated further at day 7 in all tissue aforementioned (Figure 2A–
C and S3A–C). In addition to high viremia, serum levels of dengue
virus NS1 antigen was increased on days 5 and 7 after DENV-3
infection (Figure 2D). The presence of DENV-3 in the liver tissue
of infected mice was also investigated by immunohistochemistry
assay using an anti-dengue NS3 antibody. As expected, negative
controls did not present any positive reaction (Figure 2E). On the
other hand, we found NS3-positive staining in liver of DENV-3
inoculated mice (Figure 2E), demonstrating active viral replication
of the virus in this target organ. The histoquantitative analyses
revealed elevated number of cells expressing virus antigens on day
7 after DENV-3 inoculation. Of the total number of NS3-positive
cells, 84% were hepatocytes, whereas there were also 8% kupffer
cells and 7% inflammatory cells, as assessed morphologically.
These results suggested that DENV-3 replicates in such cells,
Figure 1. Disease parameters in C57BL/6 mice infected with an adapted strain of DENV-3. (A) WT mice (n=6 mice per group) were
inoculated with different inoculums of adapted-DENV-3 (i.p) and lethality was evaluated every 12 hours for 14 days. Results are expressed as % of
survival. In Figs (B–L) WT mice (n=6 per group) were inoculated with 10LD50 (1000 PFU) of DENV-3 (i.p) and in the third, fifth or in the seventh day of
infection mice were culled and blood and tissues were collected for the following analysis: (B) Change in body weight was expressed as percentage of
initial weight loss. (C) Mechanical hypernociception was assessed daily. Results are shown as the difference between the force (g) necessary to induce
dorsal flexion of tibio-tarsal joint, followed by paw withdraw, before and after DENV-3 inoculation. In (D), hematocrit was expressed as % volume
occupied by red blood cells (left panel) and the number of platelets was shown as platelets 610
3/ml of blood (right panel). (E) Changes in vascular
permeability in the liver and lungs are shown as mg Evans blue per 100 mg of tissue (left and right panels, respectively). (F) Shows changes in Systolic
blood pressure from baseline until day 7 after infection expressed as D of blood pressure in mmHg. (G) AST (left panel) and ALT (right panel) activity
determination in plasma of control and DENV-3-infected mice was shown as U/dL of plasma. (H–L) Concentrations of IL-6, TNF-a, IFN-c IL-12/23p40
and IL-18, quantified by ELISA. Results are shown as pg per mL (serum) or pg per 100 mg (tissue). All results are expressed as mean 6 SEM and are
representative of at least two experiments. * for P,0.05 when compared to control uninfected mice. 10 LD50 corresponds to 1000 PFU of adapted-
DENV-3. ND – not detectable. NA – not assessed. NI- Not-infected. dpi – days post-infection.
doi:10.1371/journal.pntd.0001663.g001
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tissue damage (Figure 2E). Corroborating this data, marked
hepatic injury was found in DENV-3 infected mice at day 7 p.i.
(Figure 2F). Histopathological analyses revealed intense multifocal
to coalescing areas of hemorrhagic necrosis (Figure 2F). Overall,
all infected mice exhibited inflammatory infiltrates composed of
neutrophils, macrophages and lymphocytes around blood vessels
(portal and central veins) and scattered throughout the parenchy-
ma. Moderate to intense hepatocyte swelling and degeneration
were also detected. The total score in DENV-3 infected group was
13.664.2 points, in a total of 20 points, demonstrating a significant
degree of liver injury, possible directly associated with the higher
viral replication in this organ.
DENV-3 obtained from C6/36 cell culture supernatant induced
disease that was very similar to the disease induced by viral stocks
prepared from brain suspension (Figure 2G-H and S3D). UV
irradiation or heat inactivation of the virus prevented lethality and
any form of clinical manifestation of C57BL/6j mice in vivo
(Figure 2G and data not shown). Figure S4A demonstrates typing
of adapted-DENV-3 after several passages in mosquito C6/36
cells. Moreover, treatment of C57BL/6j mice with an anti-DENV-
3 polyclonal antiserum obtained from DENV-3-infected monkeys
reduced the mortality rate of adapted-DENV-3 infected mice to
approximately 50% (Figure 2H).
Plaque purification technique was performed to isolate DENV-3
clones and test the capacity of these clones to induce severe
disease. We obtained nine DENV-3 clones that were expanded in
LLC-MK2 cells and tested in vivo. These clones were designated
clones 1 to 9. BALB/c mice that were infected by the DENV-3
clones 1, 2 or 5–9 did not present any form of clinical
manifestation and therefore 100% survived to inoculation (Figure
S3D). However approximately 25% of mice infected with DENV-
3 clone 3 progressed to death (Figure S3D). In addition, all mice
infected with DENV-3 clone 4, BALB/c (Figure S3D) or C57BL/
6j (Figure S5A) strains, presented severe clinical manifestation of
disease showed by enhanced mortality rate (Figure S3D and S5A),
viremia, thrombocytopenia and hemoconcentration (Figure S5B–
D), similarly to mice infected with adapted-DENV-3 grown in C6/
36 or brain-derived DENV-3 adapted virus. Figure S4B demon-
strates typing of adapted DENV-3 (clone-4) after passage in
Figure 2. Characterization of virologic and histopathological parameters in C57BL/6j mice upon adapted-DENV-3 infection. (A–D)
C57BL/6j mice (n=6 per group) were inoculated with 10LD50 (1000 PFU) of DENV-3 (i.p) and in the third, fifth or in the seventh day of infection, mice
were culled and blood and tissues were collected for the following analysis: (A–C) Viral loads were recovered from the spleen, liver and blood,
respectively. Results are shown as the log of PFU per g of tissue or per mL of blood. (D) Shows virus NS1 antigen serum levels by ELISA and expressed
as O.D. (E–F) C57BL/6j mice (n=6 per group) were inoculated with 10LD50 (1000 PFU) of DENV-3 (i.p) and in the seventh day of infection mice were
culled and liver collected for the following analyses: (E) Liver was collected, formalin-fixed and processed into paraffin sections. Serial sections from
each tissue were stained with anti-DV NS3 antibody E1D8 (NS3) or an isotype control mouse IgG2a, and multiple sections of each tissue type were
thoroughly examined for staining. Positive staining for NS3 is brown while hematoxylin counterstain is blue. (F) shows semi-quantitative analysis of
hepatic damage and Hematoxylin & Eosin staining of liver sections of control and DENV-3-infected mice, seven days after infection (Scale Bar -
400 mm). The images presented are representative of an animal on the seventh day of infection. In (G) Viral inoculum (10LD50 or 1000 PFU) was heat
inactivated (Heat, 56uC, 60 min) or treated with UV light (UV, 15 min) before inoculation in C57BL/6j mice. Lethality was evaluated every 12 hours for
14 days. (H) WT mice (n=6 mice per group) were pretreated i.p with 100 mL of Anti-DENV-3 antiserum or control serum (pre-immune serum) before
inoculation of 10LD50 (1000 PFU) of adapted-DENV-3 (i.p). Lethality was evaluated every 12 hours for 14 days. Results are expressed as % of survival.
Results are expressed as mean 6 SEM (except for A–C, expressed as median) and are representative of at least two experiments. * for P,0.05 when
compared to control uninfected mice. 10 LD50 corresponds to 1000 PFU of adapted-DENV-3. ND- not detected. NI- not-infected. dpi- days post-
infection. NC – Negative control. HS – hepatocyte swelling. N – necrosis. D – degeneration. H – hemorrhage. OS – Overall Score.
doi:10.1371/journal.pntd.0001663.g002
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rounds of plaque purification of the adapted Clone 4 of DENV-3
and we have found that injection of a clone from the clone in adult
mice induced disease that was similar to the disease seen in mice
infected with the original clone (hematocrit: NI: 38.860.9%;
DENV-3 (7
th dpi): 4561.3%, p=0.014; platelet counts: NI:
891622610
3/mL of blood; DENV-3 (7
th dpi): 570631610
3/mL
of blood, p,0.001)
To evaluate the presence of virus in the CNS, we measured
number of DENV-3 plaques after systemic or CNS inoculation in
adult and weaning mice. Systemic injection of the virus in adult
mice resulted in detection of the virus in spleen (Figure 2A and
S6A) but no detection of virus in the brain (Figure S6B). In
contrast, systemic inoculation of the virus in weaning mice resulted
in significant detection of the virus in the brain (Figure S6B).
However, the viral load in the CNS was much higher when the
virus was inoculated directly into the brain (Figure S6B).
Immunohistochemistry analysis concurred with the findings above
and revealed that NS3 staining was only detect in newborn mice
and specially after direct injection into the brain (Figure S6C).
These data corroborate with the absence of neurologic symptoms
during disease, as well as with the lack of cytokine production in
brain tissue, as discussed above. Therefore, the adapted DENV3
strain still maintains its neurotropism in newborn mice which is
lost as mice ages and probably correlates with the development of
the blood brain barrier.
Production of IFN-c is required for host resistance to
adapted-DENV-3 primary infection
As shown in Figure 1J, during the time course of DENV-3
infection, there was an increase in levels of IFN-c in serum and
spleen from the 5
th day of infection that was maintained at the 7
th
day p.i. (Figure 1J, right and left panels, respectively). In addition,
IFN-c levels in the liver of adapted-DENV-3 mice were also
increased from day 5, reaching higher values on day 7
(NI=36611 pg/100 mg of tissue; 3 d=6466 pg/100 mg of
tissue; 5 d=109611 pg/100 mg of tissue; 7 d=216631 pg/
100 mg of tissue; n=6, p,0.05). FACS analysis of esplenocytes
isolated from DENV-3 infected mice revealed IFN-c staining in
about 12% of total cells on 7
th day after inoculation (Figure 3A).
There was an increase in expression of IFN-c in CD4
+ T cells,
CD8
+ T cells, CD3
2NK1.1
+ NK cells, and CD3
+NK1.1
+ NKT
cells. Significantly, over 46% of CD4
+ T cells, 36% of CD8
+ T
cells and 36% of CD3
2NK1.1
+ NK cells and 35% of
CD3
+NK1.1
+ NKT cells were IFN-c
+ at this period in comparison
with cells of non-infected mice (Figure 3A).
To investigate in vivo the role played by IFN-c during DENV-3
infection, wild type (WT) and IFN-c deficient (IFN-c
2/2) mice
were inoculated with 1LD50 of adapted DENV-3 and mortality
rate and disease parameters were evaluated. After infection, 100%
of IFN-c
2/2 mice were dead before day 9 of infection, while less
than 30% of WT mice had succumbed to infection after 14 days of
inoculation of DENV-3 (Figure 3B). In fact, approximately 75% of
IFN-c
2/2 mice were already dead at day 6 after infection
(Figure 3B), which led us to perform the subsequent analysis on
day 5 after infection. The early lethality of IFN-c
2/2 mice was
associated with increased DENV-3 replication. As early as the 3
rd
day of DENV-3 inoculation, viremia in IFN-c
2/2 mice was
detectable (WT: not detectable; IFN-c
2/2: 2.9610
3 PFU/mL of
blood, n=4, p=0,03). Viremia was almost 2log higher in IFN-c
2/
2 mice in comparison to WT mice at 5 days after infection
(Figure 3C). Indeed, at this time point, there was marked increase
of viral load in spleen (Figure 3D, left panel) and liver (Figure 3D,
right panel) of infected IFN-c
2/2 mice. Moreover, NS3
+ staining
in liver was strikingly higher in infected IFN-c
2/2 mice when
compared with their WT littermates (Figures 3E). Again, the
hepatocytes were the predominant cell stained for NS3 protein,
representing almost 90% of positive cells. Of interest, the virus
could not be detected in the brain of WT and IFN-c
2/2 infected
mice (data not shown).
In addition to greater lethality rates and to enhanced viral
replication, IFN-c
2/2 mice presented more severe manifestation
of disease after infection (Figure 3F–J). Hypernociception initiated
earlier and remained increased at all time points evaluated
(Figure 3F). IFN-c
2/2 mice also had more marked thrombocy-
topenia (Figure 3G, right panel), significant greater increase in
hematocrit values (Figure 3G, left panel), and more drastic
reduction in systolic blood pressure (Figure 3H) than infected WT
mice.
IFN-c
2/2 mice showed greater liver injury after DENV-3
infection, as demonstrated by increased AST activity in plasma
(Figure 3I). There were marked histopathological alterations in
liver of IFN-c
2/2 mice which were more intense than those of
WT mice (Figure 3J) but similar to those described in WT mice
infected with a higher inoculum (10LD50) (Figure 2F). It is
noteworthy that the inoculum used (1LD50) was capable of causing
only mild disease in WT mice. Therefore, the data shown here
demonstrate that IFN-c is produced early during infection and
plays an important role in mediating host resistance to DENV-3
infection.
IFN-c-mediated protection to adapted-DENV-3 infection
depends on enhanced NOS2-expression and nitric oxide
production
One of the well known effector mechanisms induced by IFN-c
after viral infections is enhancement of NOS2 expression in
phagocytes. To assess the participation of this pathway in host
response to dengue infection, we evaluated the kinetics of NOS2
expression and NO production after DENV-3 infection. As shown
in Figure 4A, there was an increase in NOS2 mRNA expression in
spleen starting on day 3 after DENV-3 inoculation and rising
rapidly on days 5 and 7 post infection. In accordance with these
data, WT infected mice showed increased NOS2-positive staining
in liver from day 5 after infection, peaking at day 7 after infection
(Figure 4B), virtually only in infiltrating leukocytes. In addition,
there was elevation in DAF staining of esplenocytes isolated from
DENV-3-infected mice, showing increased production of NO in
spleen on day 7 post-inoculation (Figure 4C).
Consistently with the ability of IFN-c to induce NOS2 mediated
NO production, NOS2 mRNA expression in spleen was markedly
decreased in IFN-c
2/2 mice (Figure 4D). Similarly, immunohis-
tochemistry analysis revealed that NOS2 positive-cells were almost
absent in liver on day 5 post-infection (Figure 4E). Furthermore,
there was no production of NO by dendritic cells infected with
DENV-3 in vitro (Figure S7). However, treatment of WT bone
marrow derived dendritic cells with IFN-c prior to DENV-3
infection resulted in production of significant amounts of NO, an
effect that was absent in IFNGRI
2/2 cells (Figure S7). These data
suggest that NOS2-mediated NO production during DENV-3
infection is controlled by IFN-c.
To assess the role played by NOS2-induced NO during DENV
infection, NOS2
2/2 mice and their WT littermates were
inoculated with 1LD50 of adapted DENV-3 and lethality rate
and disease parameters were evaluated. As shown in Figure 5A,
NOS2
2/2 mice were markedly susceptible to DENV infection.
While all knockout animals were dead by the 10
th day of infection,
only 20% of WT mice had succumbed to infection after 14 days of
inoculation of DENV-3. High viremia has been detected on day 5
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2/2 mice (WT:7.8610
3 PFU/
mL; NOS-2
2/2:8 610
5 PFU/mL of blood, n=6, p=0.01).
Viremia in NOS-2
2/2 was also higher in comparison to WT
littermates at day 7 post-DENV-3 inoculation (Figure 5B). Viral
load in spleen (Figure 5C), and liver (Figure 5D) were also
significantly higher in NOS2
2/2 than in WT mice at day 7 post-
DENV-3-inoculation. In addition, there was also increase in
number of NS3-positive cells in liver in comparison with WT
Figure 3. IFN-c production is required for host resistance to adapted-DENV-3 primary infection. (A) WT mice (n=4 mice per group) were
inoculated with 10LD50 (1000 PFU) of DENV-3 (i.p) and seven days later, mice were culled, and splenic cells isolated for assaying IFN-c production by
cellular staining with labeled antibodies and FACS analysis. Results are expressed as % of IFN-c-positive cells in each population. (B) WT and IFN-c
2/2
mice (n=8 per group) were inoculated with 1LD50 (100 PFU) of DENV-3 (i.p) and lethality was evaluated every 12 hours during 14 days. Results are
expressed as % of survival. In (C–J), WT and IFN-c
2/2 mice (n=6 per group) were inoculated with 1LD50 (100 PFU) of DENV-3 (i.p) and in the fifth day
of infection mice were culled and blood and tissues were collected for the following analysis: (C–D) Viral loads were recovered from the blood (C),
spleen and liver (D, left and right panels), respectively. Results are shown as the log of PFU per mL of blood or per g of tissue. (E) Serial sections from
each liver were stained with anti-DV NS3 antibody E1D8 (NS3) or an isotype control mouse IgG2a (IgG2a data not shown), and multiple sections of
each tissue type were thoroughly examined for staining. Positive staining for NS3 is brown while hematoxylin counterstain is blue. Results are
expressed as number of NS3-positive hepatocytes. (F) Mechanical hypernociception was assessed daily. Results are shown as the difference between
the force (g) necessary to induce dorsal flexion of tibio-tarsal joint, followed by paw withdraw, before and after DENV-3 inoculation. In (G), hematocrit
was shown as % volume occupied by red blood cells (left panel) and the number of platelets was shown as platelets610
3/ml of blood (right panel).
(H) Changes in Systolic blood pressure from baseline until day 5 after infection expressed as D of blood pressure in mmHg. In (I), AST activity
determination in plasma, shown as U/dL of plasma. (J) shows semi-quantitative analysis of hepatic damage (histopathological analysis performed as
modified from Paes et al, 2009) and Hematoxylin & Eosin staining of liver sections of control and WT and IFN-c
2/2 DENV-3-infected mice, five days
after infection. Scale bars - 400 mm. The images presented are representative of an animal on the fifth day of infection. All results are expressed as
mean 6 SEM (except for C–D, expressed as median) and are representative of at least two experiments. * for P,0.05 when compared to control
uninfected mice. # fo P,0.05 when compared to WT infected mice. 10 LD50 corresponds to 1000 PFU of adapted-DENV-3. 1LD50 corresponds to 100
PFU of adapted-DENV-3. ND – not detectable. NI- Not-infected. dpi – days post-infection. HS – hepatocyte swelling. N – necrosis. D – degeneration. H
– hemorrhage. OS – Overall Score.
doi:10.1371/journal.pntd.0001663.g003
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2/2 mice
showed significant mechanical hypernociception (Figure 5F), on
days 6 and 7 after DENV-3 inoculation, in comparison with WT
infected mice. NOS2
2/2 also showed greater thrombocytopenia,
intense hemoconcentration (Figure 5G right and left panels,
respectively) and marked reduction in systolic blood pressure
(Figure 5H) in comparison with WT infected mice. Finally, AST
activity in serum was more intense in knockout mice in
comparison to DENV-3 infected WT controls (Figure 5I).
Similarly to the situation found in infected IFN-c
2/2 mice,
important histopathological alterations were found in liver of
NOS2
2/2 mice after DENV-3 inoculation (Figure 5J). Histopath-
ological analysis revealed greater disease scores in the NOS2
2/2
group than in WT mice (Figure 5J). Of note, all alterations seen in
NOS2
2/2-infected mice were not due to a reduction in IFN-c
production after DENV-3 infection (for example, at day 7 in
serum: NI=not-detectable; WT=35306317 pg/mL of serum;
NOS2
2/2=29686619 pg/mL of serum, n=6, p=0,44).
After DENV-3 inoculation, there were detectable levels of both
IL-12/23p40 and IL-18 cytokines in the spleen of WT mice
already on day 5 of infection (Figure 1L). The early production of
these cytokine is consistent with their possible role in the induction
of IFN-c during DENV-3 infection. As seen in the DENV-2
mouse model [30], there was drastic reduction in production of
IFN-c after DENV-3 infection in IL-12p40
2/2 mice, which are
deficient for both IL-12 and IL-23 cytokine production, and also in
IL-18 binding protein (IL-18 bp) treated-WT mice (Figure S8A) or
IL-18
2/2 mice (NI=not-detectable; WT=44356562 pg/
100 mg of spleen; IL-18
2/2=23736552 pg/100 mg of spleen,
n=6, p=0,029). Interestingly, combined depletion of both
cytokines resulted in total abrogation of IFN-c staining in spleen
cells after DENV-3 infection (Figure S8A). In accordance with
these data, IL-12p40
2/2 mice, IL-18
2/2 mice or IL-12p40
2/2
mice treated with IL-18 bp (IL12p40
2/2+IL18 bp) were more
susceptible to DENV-3 infection (Figure S8B). While only 20% of
WT mice were dead at the end of 14 days after infection, all
knockout mice had succumbed to infection until day 9 of DENV-3
inoculation. Significantly, earlier deaths were accompanied by
elevation in viral loads in blood of IL-12p40
2/2, IL-18
2/2 or IL-
12p40
2/2 treated with IL18 bp mice (Figure S8C). Moreover,
combined cytokine depletion resulted in intense hemoconcentra-
tion (Figure S8D, left panel), which was greater than in the other
infected groups. Thrombocytopenia was also increased but there
was no difference between the infected groups (Figure S8D, right
panel).
Discussion
Several important questions in dengue immunopathogenesis are
difficult to address without adequate animal models of infection
and disease. In the present study, we described a novel model of
DENV-3 infection in adult immunocompetent mice which mimics
the major manifestations of severe dengue infection in humans.
We demonstrated that the inoculation of the mouse-adapted
DENV-3 strain by a peripheral route induced an inoculum-
dependent lethality preceded by severe disease development in
adult immunocompetent mice. The major alterations found
during disease development were: 1) Lethality preceded by
development of hemoconcentration, thrombocytopenia, elevated
transaminase levels associated with important liver injury, marked
Figure 4. IFN-c controls NOS2-mediated NO production during adapted-DENV-3 infection. (A–C) WT mice (n=6 mice per group) were
inoculated with 10LD50 (1000 PFU) of adapted-DENV-3 (i.p) and 3, 5 or 7 days after infection, mice were culled and tissue were collected for the
following analysis: (A) Determination of NOS2 RNA expression by qPCR in spleen of control and DENV-3 infected mice. Results are shown as fold
increase over basal expression in naive mice. (B) Determination of NOS2 staining by immunohistochemistry in liver sections of control and DENV-3
infected mice. Results are expressed as number of positive cells per mm
2 of liver. (C) Esplenocytes were incubated with DAF-2DA and fluorescence
determined. Results are expressed as fold increase in fluorescence over stained cells of naive mice. (D–E), WT and IFN-c
2/2 mice (n=6 per group)
were inoculated with 1LD50 (100 PFU) of DENV-3 (i.p) and in the fifth day of infection mice were culled and tissues were collected for the following
analysis: (D) Determination of NOS2 RNA expression by qPCR in spleen of WT and IFN-c
2/2 DENV-3 infected mice. Results are shown as fold increase
over basal expression in naive mice. (E) Determination of NOS2 staining by immunohistochemistry in liver sections of WT and IFN-c
2/2 DENV-3
infected mice. Results are expressed as number of positive cells per mm
2 of liver. Results are expressed as mean 6 SEM and are representative of at
least two experiments. * for P,0.05 when compared to control naive mice. # for P,0.05 when compared to WT infected mice. 10LD50 corresponds
to 1000 PFU of DENV-3. 1LD50 corresponds to 100 PFU of DENV-3. dpi – days post-infection. NI – Not-infected.
doi:10.1371/journal.pntd.0001663.g004
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Increased levels of cytokines, including IFN-c, IL-6, TNF-a, Il-12/
23p40 and IL-18; 3) Increased viral load in spleen, liver and blood,
virus NS1 antigen serum levels and NS3-staining in hepatocytes of
infected mice. All these findings indicate that the mouse model
described here will add to existing models [7,16,45–46] and
together they may aid in the study of the immunopathogenesis of
dengue disease.
The difficulty in developing a mouse model for DENV is largely
the result of the inability of human clinical isolates to replicate well
in mice [7,16,45,47,48]. Previously, our group has developed an
experimental model of infection with an adapted DENV-2 strain
that mimics several clinical parameters seen in human disease.
This model has allowed the study of some mechanisms mediating
protection or those associated with the development of severe
disease [22,24–28,30]. One important key point facing dengue
researchers is how a viral strain or serotype variation and infection
sequence affects the conditions for immune protection and
enhancement [48]. In this context, it becomes extremely necessary
the establishment of primary and secondary mouse models with all
DENV serotypes to verify if this mechanisms of protection and
disease share similarities or differences in the face of different
context of infections, and also to test the efficacy of possible
vaccine candidates and antiviral compounds. Accordingly, using
Figure 5. NOS2
2/2 mice are more susceptible to adapted-DENV-3 infection. (A) WT and NOS2
2/2 mice (n=8 per group) were inoculated
with 1LD50 (100 PFU) of DENV-3 (i.p) and lethality was evaluated every 12 hours during 14 days. Results are expressed as % of survival. In (B–J), WT
and NOS2
2/2 mice (n=6 per group) were inoculated with 1LD50 (100 PFU) of DENV-3 (i.p) and in the seventy day of infection mice were culled and
blood and tissues were collected for the following analysis: (B–D) Viral loads were recovered from the blood (B), spleen (C) and liver (D), respectively.
Results are shown as the log of PFU per per mL of blood or g of tissue. (E) Serial sections from liver of WT and NOS2
2/2 mice were stained with anti-
DV NS3 antibody E1D8 (NS3) or an isotype control mouse IgG2a (IgG2a data not shown), and multiple sections of each tissue type were thoroughly
examined for staining. Positive staining for NS3 is brown while hematoxylin counterstain is blue. Results are expressed as number of NS3-positive
hepatocytes. (F) Mechanical hypernociception was assessed daily. Results are shown as the difference between the force (g) necessary to induce
dorsal flexion of tibio-tarsal joint, followed by paw withdraw, before and after DENV-3 inoculation. In (G), hematocrit was shown as % volume
occupied by red blood cells (left panel) and the number of platelets was shown as platelets 610
3/ml of blood (right panel). (H) Changes in Systolic
blood pressure from baseline until day 5 after infection expressed as D of blood pressure in mmHg. In (I), AST activity determination in plasma was
shown as U/dL of plasma. (J) shows semi-quantitative analysis of hepatic damage (histopathological analysis performed as modified from Paes et al,
2009) and Hematoxylin & Eosin staining of liver sections of control and WT and NOS2
2/2 DENV-3-infected mice, seven days after infection. Scale Bar -
400 mm. The images presented are representative of an animal on the seventh day of infection. All results are expressed as mean 6 SEM and are
representative of at least two experiments. * for P,0.05 when compared to control uninfected mice. # for P,0.05 when compared to WT infected
mice.1LD50 corresponds to 100 PFU of adapted-DENV-3. NI- Not-infected. dpi – days post-infection. HS – hepatocyte swelling. N – necrosis. D –
degeneration. H – hemorrhage. OS – Overall Score.
doi:10.1371/journal.pntd.0001663.g005
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generated an adapted strain of DENV-3 by several intracerebral
(ICR) passages of a non-adapted human DENV-3 (genotype I)
into weaning and progressively older BALB/c mice. Interestingly,
this same non-adapted human strain was able to induce
meningoencephalitis and behavioral changes that preceded
lethality in adult C57BL/6 mice when inoculated by i.c route,
however without causing any systemic clinical manifestation in
these mice [49]. Importantly, the infection of immunocompetent
mice with this new adapted-DENV-3 strain showed many
similarities with the disease found in the DENV-2 infection model
described before [22,24] and also with the disease seen in humans.
We believe that the characterization of these two DENV strains
and the establishment of primary and secondary mouse models
with all DENV serotypes will aid in evaluation of mechanisms of
protection and of disease during distinct context of infections, as
well as to test the efficacy of possible vaccine candidates and
antiviral compounds.
Meanwhile, our studies demonstrated that after adaptation
process, the adapted DENV-3 strain acquired the ability to induce
systemic severe disease in adult immunocompentent mice (BALB/
c or C57BL/6 strains) when inoculated by a peripheral route,
without affecting the CNS, resembling the major manifestations
seen in infected humans. It is important to note that the virus kept
its ability to replicate in the CNS when given directly in the brain.
Previous studies have also shown that the adaptation process is
necessary for an efficient infection and occurrence of disease
symptoms. Tesh and colls (2001) [50] showed that sequential series
of liver-to-liver passages of YFVs in hamsters are necessary to lead
the generation of more virulent strains. In addition, Shresta and
colleagues (2004) [51] have generated a novel virulent DENV-2
strain, D2S10, by alternately passages between mosquito cells and
non-neuronal tissues of mice. Using AG129 mice (that lack IFN
type I and II receptors), they have demonstrated that D2S10 strain
was more virulent than the parental strain, PL046, causing a lethal
but nonparalytic disease. Sequence comparisons between D2S10
and the parental strain (PL046) revealed amino acid change
difference in a conserved region of E gene, suggesting a role for
these particular residues in determining viral virulence and
pathogenesis in vivo [51]. Besides this, a full molecular analysis is
necessary to identify the viral determinants responsible for this
strong phenotype of dengue disease in the present model, but this
is beyond the scope of the present study.
Hallmark features of human DHF/DSS are vascular leakage,
higher viral burden, elevated levels of serum cytokines, hypoten-
sion and occurrence of thrombocytopenia [52–53]. Hence, all
these features were observed in the present study, demonstrating
that the present mouse model mimics severe dengue disease in
humans. We, therefore, suggest that this model of dengue infection
may be useful for the study of the pathophysiology of severe
dengue disease. Epidemiological observations demonstrated that
only a very small percentage of infections results in severe disease
(DHF/DSS), represented as a tip of the pyramid and that this
incidence varies significantly between primary and secondary
DENV infections. It has been documented that a secondary
DENV infection is the single and the most important risk factor for
severe dengue disease manifestation, although, severe disease
during primary infections is also reported [54,55–59]. It has been
hypothesized that subneutralizing levels of antibodies facilitate the
entry of viral particles in permissive cells, enhancing viral loads,
and exacerbating disease manifestation during secondary infection
[60]. Experimental DENV models support this hypothesis and
suggest that disease severity is directly associated with enhanced
viral replication during infection [45–46]. In the present exper-
imental model, lethality hematological and other pathological
alterations in infected mice was dependent on the size of the
inoculum and were observed in mice presenting elevated viral
loads. Of note, infected IFN-c-deficient and NOS2-deficient mice
presented heightened viral replication, in parallel with elevated
hematocrits, thrombocytopenia, and liver injury. Thus, although
our studies do not mimic the human situation of 2 sequential
infections with distinct viral serotypes, these results mimic up to
the extent in which we demonstrated that disease in this model is
inoculum-dependent, what bears relevance to human disease.
In addition to the features above, both clinical and experimental
observations suggest that there is important liver involvement
during dengue infection [61–63]. For example, elevated serum
transaminase levels during dengue infection is common and is
usually correlated with disease severity [8,27,43,64–66]. In
accordance, AST and ALT transaminase levels were elevated in
the present study mainly on day 7 of infection, correlating with the
peak of disease and hepatic damage in the present model. Further,
intense necro-hemorrhagic hepatitis, hepatocellular swelling and
steatosis associated with vascular damage, which is characteristic
of dengue-induced hepatitis in human liver [64] were observed in
liver of mice inoculated with a lethal inoculum of adapted-DENV3
on day 7 post-infection. Intravital confocal microscopy of the liver
microvasculature revealed a significant increase in hepatocyte
diameter and severe reduction in sinusoidal perfusion. In this
sense, liver failure may be caused by reduction of sinusoidal
perfusion (directly promoting tissue isquemia) and also by diffuse
hepatocyte necrosis caused by DENV infection and replication
and/or by products derived from inflammatory leukocytes. Our
data on the liver injury showed many similarities to those
demonstrated by Paes et al (2005, 2009) [43,65], using a non-
adapted DENV-2 in BALB/c mice and even to histopathological
findings from DF and DHF postmortem tissue specimens [66–68].
Of note, we showed the presence of virus (or NS3 protein) in liver,
mainly in hepatocytes. All these findings indicate the liver as an
important target organ of DENV infection and replication,
suggesting an important association between virus replication
and hepatic damage as demonstrated by other studies [43,45–
46,65,67].
Its well knows that the IFN system is essential in the context of
DENV infection [69–70]. Recently, we have demonstrated that
optimal IFN-c production during DENV-2 infection is controlled
by the cytokines IL-12 and IL-18. Moreover, we showed that one
of the mechanisms triggered by IFN-c during host response to
DENV-2 infection is the production of nitric oxide, an important
virustatic metabolite. In this sense, to validate this novel mouse
model of DENV-3 infection and to verify whether this pathway is
also involved in response against different serotypes, we investi-
gates the role of IFN-c in the context of infection with the adapted-
DENV-3 strain. In the present experimental model, IFN-c is
produced early (day five of infection) in infected-WT mice and the
absence of IFN-c action was associated with earlier lethality, more
severe disease and higher viral loads even during infection with
sublethal inoculums. These findings are in agreement with Shresta
and coworkers (2004) [51] that demonstrated the importance of
IFN-c and type I IFNs in restricting viral replication and
eliminating virus after primary DENV-2 infection. The correlation
between increased IFN-c production and higher survival rates in
DHF patients also supports this idea [70]. Importantly, Gunther
and colleagues (2011) [64] have demonstrated in a human
challenge model of DENV infection that only sustained IFN-c
production was associated with protection against fever and
viremia during the acute phase of illness [71]. In our studies,
enhanced viral replication in IFN-c-deficient mice was associated
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hematological alterations and hepatic damage. These data
strongly suggest that in the absence of IFN-c, there are intense
and uncontrolled viral replication, that lead to severe disease
manifestation and lethality, already in early times of infection.
Accordingly, previous studies have shown that IFN-c likely
contributes to viral clearance through several mechanisms,
including direct inhibition of viral replication [72]. Of note, quite
similar to that seen in the DENV-2 model [30], the combined
action of IL-12 and IL-18 is also necessary for optimal IFN-c
production and control of DENV-3 infection.
Production of reactive nitrogen intermediates via increase in
NOS2 expression is among the main IFN-c-induced pathways
involved in control of infections [73]. In fact, it has been shown
that NOS2 expression is increased after DENV infection and that
its expression in PBMCs of DF patients. This increase in NOS2
expression was found to correlate with the late acute phase of
disease and preceded the clearance of DENV from monocytes
[74]. NO production was also associated with less severe disease
manifestation disease in humans [75]. Finally, NO is able to
inhibit DENV replication in vitro [76–77]. In the present study,
NOS2 expression is increased during adapted DENV-3 infection
in different targets organs of infection and this expression was
controlled by IFN-c. Nitric oxide production was also observed in
esplenocytes of DENV-3 infected mice (ex vivo) and in DENV-
infected DCs stimulated by IFN-c in vitro. Of note, NOS2
2/2 mice
had elevated lethality, more severe disease manifestation and
increased viral loads, even in the presence of high levels of IFN-c.
Thus, these data demonstrated here show that NOS2-mediated
NO production after primary DENV-3 infection also seems to be
an important pathway involved in control of DENV-3 replication
and disease evolution. These data are quite similar with the results
found in the DENV-2 infection model, suggesting that this
mechanism is conserved protective pathway in host response to
both DENV-2 and DENV-3 serotypes. These findings support
that strategies aiming to potentiate IFN-c-induced NO production
could be useful during the control of primary infection by Dengue
virus.
In summary, we report a model of DENV-3 infection in
immunocompetent mice and describe the clinical, immunopath-
ological and virological features induced by inoculation of the
virus. These features clearly resemble the manifestations of severe
dengue disease in humans. We have also demonstrated the crucial
role of IFN-c and NOS2-derived NO in host resistance to DENV
infection, a protective pathway involved in resistance to other
DENV strains. Therefore, this model represents a significant
advance in animal models of severe dengue disease and may
contribute to the elucidation of the immunopathogenesis of disease
and of protective mechanisms associated to infection. In addition,
the model may be a relevant tool for vaccine and drug
development.
Supporting Information
Figure S1 Disease parameters in BALB/c mice infected
with an adapted strain of DENV-3. (A) WT mice (n=6 mice
per group) were inoculated with different inoculums of adapted-
DENV-3 (i.p) and lethality was evaluated every 12 hours for 14
days. Results are expressed as % of survival. In Figs (B–E) WT
mice (n=6 per group) were inoculated with 1LD50 (100 PFU) of
DENV-3 (i.p) and in the third, fifth or in the seventh day of
infection mice were culled and blood and tissues were collected for
the following analysis: (B) Change in body weight was expressed as
percentage of initial weight loss. (C) Mechanical hypernociception
was assessed daily. Results are shown as the difference between the
force (g) necessary to induce dorsal flexion of tibio-tarsal joint,
followed by paw withdraw, before and after DENV-3 inoculation.
(D) Hematocrit was expressed as % volume occupied by red blood
cells (left panel) and the number of platelets was shown as platelets
610
3/ml of blood (right panel) and. In (E) AST and ALT activity
determination in plasma of control and DENV-3-infected mice
was shown as U/dL of plasma. Results are expressed as mean 6
SEM and are representative of at least two experiments. * for
P,0.05 when compared to control uninfected mice. 1 LD50
corresponds to 100 PFU of DENV-3. NI – not-infected. dpi- days
post-infection.
(TIF)
Figure S2 Confocal microscopy in liver microvascula-
ture upon DENV-3 infection. (A-B) C57BL/6j mice (n=5 per
group) were inoculated with 10LD50 (1000 PFU) of DENV-3 (i.p)
and in the seventh day of infection mice were anesthetized, cells
were fluorescently labeled by rhodamine 6G (A) or phycoerythrin-
anti PECAM-1 antibody (B) to assess hepatocyte size and the
percentage of perfused sinusoids, respectively. Hepatocyte size is
expressed as the length of longest cell axis and perfused sinusoids
as % of the area fraction stained by the antibody. The images
presented are representative of an animal on the seventh day of
infection.All results are expressed as mean 6 SEM and are
representative of at least two experiments. * for P,0.05 when
compared to control uninfected mice. 10 LD50 corresponds to
1000 PFU of adapted-DENV-3. dpi- days post-infection. NI: Not
infected.
(TIF)
Figure S3 Viral load and lethality rates of BALB/c mice
upon adapted-DENV-3 inoculation. (A–C) WT mice and
their controls (n=6-7 per group) were inoculated with 1LD50 (100
PFU) of DENV-3 (i.p) and in the third, fifth or in the seventh day
of infection mice were culled and blood and tissues were collected
for the following analysis: (A–C) Viral loads were recovered from
the spleen, liver and blood, respectively. Results are shown as the
log of PFU per g of tissue or per mL of blood. In (D), plaque
purification technique was performed for isolation of DENV-3
clones (Clone 1–9) and mice were inoculated with 100 PFU of
each clone and lethality was evaluated every 12 hours for 14 days.
Results are expressed as % of survival. * for P,0.05 when
compared to control uninfected mice. 1 LD50 corresponds to 100
PFU of adapted-DENV-3. NI – not infected. ND- not detectable.
dpi- days post-infection.
(TIF)
Figure S4 Typing of adapted DENV-3. (A) Agarose gel
electrophoresis displaying amplicons of specific PCR with primers
D1 and TS3 (290 bp). Lane 1, DNA Ladder 50 bp, Lane 2,
empty. Lane 3: Non-adapted DENV-3 (positive control). Lane 4-6:
adapted DENV-3 (several passages in C6/36 cells). Lane 7: primer
mix. (B) Polyacrylamide gel electrophoresis displaying amplicons
of specific PCR with primers D1 and TS3 (290 bp). Lane 1, Clone
4 of the adapted DENV-3, Lane 2, DNA Ladder 50 bp. Lane 3:
primer mix. Lane 4: Non-adapted DENV-3 (positive control).
(TIF)
Figure S5 Inoculation of Clone 4 in C57BL/6j mice
mimics the disease and mortality seen after infection
with adapted-DENV-3. (A) C57BL/6j mice (n=5 mice per
group) were inoculated with different inoculums of plaque purified
Clone 4 (i.p) and lethality was evaluated every 12 hours for 14
days. Results are expressed as % of survival. In Figs (B–D)
C57BL/6j mice (n=6 per group) were inoculated with 10LD50
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day of infection mice were culled and blood were collected for the
following analysis: (B) Viral load was recovered from the blood.
Results are shown as the log of PFU per mL of blood. (C–D) The
number of platelets was shown as platelets 610
3/ml of blood (C)
and hematocrit as % volume occupied by red blood cells (D). * for
P,0.05 when compared to control uninfected mice. 10LD50
corresponds to 100 PFU of Clone 4. NI – not infected. ND- not
detectable. dpi- days post-infection.
(TIF)
Figure S6 Virus analysis in brain and spleen of newborn
BALB/c mice upon adapted-DENV-3 i.p and i.c inocu-
lation. BALB/c newborn mice (n=4–7 per group) were
inoculated with 20 PFU of adapted-DENV-3 by i.c or i.p route
and 5 days after infection spleen and brain were collected for the
following analysis: (A–B) Viral loads were recovered from the
brain and spleen, respectively. Results are shown as the log of PFU
per g of tissue. (C) Semiquantitative analysis of multiple sections of
brain samples from i.c or i.p DENV-3 inoculated mice on day 5
after infection. Results are shown as number of positive cells. * for
P,0.05 when compared to control uninfected mice. # for P,0.05
when compared to i.c newborn infected mice. i.c – intracerebral.
i.p – intraperitoneal. NI – not infected. ND – Not detectable.
(TIF)
Figure S7 Enhanced NO production by DCs after
adapted-DENV-3 infection is controlled by IFN-c. Bone
marrow derived dendritic cells were infected with DENV-3 (MOI
0,05 PFU/cell) in the presence or not of IFN-c. After 72 hours,
cell supernatant was collected for nitrite quantification by Griess
reaction. Results are expressed as and mM of nitrite in medium.
Results are expressed as mean 6 SEM and are representative of at
least two experiments. * for P,0.05 when compared to control
uninfected cells, and # for P,0.05 when compared to DENV-3-
infected cells.
(TIF)
Figure S8 IL-12 and IL-18 act in synergism to induce
IFN-c production and resistance to DENV-3 infection. (A)
WT and IL-12/p40
2/2 mice (n=4 mice per group) treated or not
with IL-18 bp (daily i.p. injection of 1 mg/kg of protein) were
inoculated with 1LD50 (100 PFU) of DENV-3 (i.p), culled on day
seven of infection and esplenocytes isolated for assaying IFN-c
production by cellular staining with labeled antibodies and FACS
analysis. Results are expressed as % of IFN-c-positive cells in each
population. (B) WT, IL-12/p40
2/2 mice (n=6 mice per group)
treated or not with IL-18 bp (daily i.p. injection of 1 mg/kg of
protein) and IL-18
2/2 were inoculated with 1LD50 (100 PFU) of
DENV-3 (i.p) and lethality was evaluated every 12 hours for 14
days. Results are expressed as % of survival. (C, D) WT and IL-
12/p40
2/2 mice (n=4 mice per group) treated or not with IL-
18 bp (daily i.p. injection of 1 mg/kg of protein) were inoculated
with 1LD50 (100 PFU) of DENV-3 (i.p), culled on day seven of
infection and tissues collected for (C) Viral load quantification in
blood of WT, IL-12p40 treated or not with IL-18 bp (daily i.p.
injection of 1 mg/kg of protein) and IL-18
2/2 upon DENV-3
infection Results are shown as the log of PFU per mL of blood; (D)
Hematocrit measurement, shown as % volume occupied by red
blood cells (left panel) and number of platelets shown as platelets
610
3/ml of blood (right panel). Results are expressed as mean 6
SEM (except for C, expressed as median) and are representative of
at least two experiments. * for P,0.05 when compared to control
uninfected mice. # for P,0.05 when compared to WT infected
mice. 1 LD50 corresponds to 100 PFU of DENV-3. NI – not-
infected.
(TIF)
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